Heat Biologics Inc (NASDAQ:HTBX) saw a significant growth in short interest in March. As of March 31st, there was short interest totalling 2,869,626 shares, a growth of 14.5% from the March 15th total of 2,506,640 shares. Based on an average daily volume of 1,611,057 shares, the short-interest ratio is presently 1.8 days.
Shares of Heat Biologics (NASDAQ:HTBX) opened at 0.678 on Friday. The stock’s 50 day moving average price is $0.77 and its 200-day moving average price is $1.00. Heat Biologics has a 52-week low of $0.50 and a 52-week high of $3.35. The stock’s market cap is $22.73 million.
Heat Biologics (NASDAQ:HTBX) last posted its quarterly earnings data on Friday, March 31st. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.07) by $0.05. The business had revenue of $0.12 million for the quarter, compared to analysts’ expectations of $0.13 million. On average, analysts predict that Heat Biologics will post ($0.63) earnings per share for the current fiscal year.
A number of large investors have recently bought and sold shares of the stock. Oxford Asset Management bought a new stake in Heat Biologics during the fourth quarter valued at $274,000. Sabby Management LLC bought a new stake in Heat Biologics during the first quarter valued at $2,176,000. KCG Holdings Inc. boosted its stake in Heat Biologics by 35.3% in the first quarter. KCG Holdings Inc. now owns 175,769 shares of the biopharmaceutical company’s stock valued at $156,000 after buying an additional 45,831 shares during the last quarter. Finally, Vanguard Group Inc. boosted its stake in Heat Biologics by 132.4% in the first quarter. Vanguard Group Inc. now owns 591,098 shares of the biopharmaceutical company’s stock valued at $526,000 after buying an additional 336,744 shares during the last quarter. Hedge funds and other institutional investors own 1.78% of the company’s stock.
A number of research analysts have commented on the company. Noble Financial restated a “buy” rating on shares of Heat Biologics in a research note on Sunday, May 14th. Zacks Investment Research lowered Heat Biologics from a “buy” rating to a “hold” rating in a research report on Friday, May 5th.
About Heat Biologics
Heat Biologics, Inc is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT).
Receive News & Ratings for Heat Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics Inc and related companies with MarketBeat.com's FREE daily email newsletter.